Automated, cost-effective production of mRNA vaccines as well as cell and gene therapeutics

“The system will enable automated, component-based, flexible and validatable production”

07-Nov-2023 - mRNA-based vaccines and gene/cell therapeutics open up new possibilities for medical practitioners in the fight against cancer and infectious or hereditary diseases. However, manufacturing these innovative pharmaceuticals is an expensive and time-consuming process. The Fraunhofer RNAuto ...

Cellectis enters into strategic collaboration and investment agreement with AstraZeneca

Cellectis to receive up to $245M in cash, with potential for additional milestones, plus tiered royalties

03-Nov-2023 - Cellectis announced it has entered into (i) a Joint Research Collaboration Agreement (the “Collaboration Agreement”, (ii) an investment agreement relating to an initial equity investment of $80M, and (iii) a memorandum of understanding (the “MOU”) relating to an additional equity investment of ...

Biocytogen Announces Collaboration with FineImmune to Develop TCR-Mimic Antibody-Based Cell Therapy

19-Sep-2022 - Biocytogen Pharmaceuticals (Beijing) Co., Ltd. announced a strategic collaboration with Guangzhou FineImmune Biotechnology Co., LTD. to co-develop cell-based therapeutic drugs targeting intracellular tumor-associated antigens. Biocytogen will use its proprietary TCR-mimic antibody platform to ...

Cellino aims to significantly expand patient access to cell therapies with autonomous end-to-end manufacturing

Leaps by Bayer leads $80M Series A Financing for Cellino Biotech to Autonomize Stem Cell Therapy Manufacturing

28-Jan-2022 - Cellino Biotech, Inc., an autonomous cell therapy manufacturing company, announced the completion of a Series A financing of $80 million, led by the impact investment arm of Bayer AG – Leaps by Bayer – 8VC, and Humboldt Fund. New investors in the round include Felicis Ventures and others, joining ...

New understanding of cell stability with potential to improve immune cell therapies

Findings highlight pathway to remove unstable cells

29-Jul-2021 - Research in mice, published in Science Immunology by researchers at the Babraham Institute, UK and VIB-KU Leuven, Belgium, provides two solutions with potential to overcome a key clinical limitation of immune cell therapies. Regulatory T cells have potential in treating autoimmunity and ...

Siemens and Exyte join forces to deliver integrated solutions for fast-track construction of smart biotech facilities

Covid-19 poses major challenges for developing and mass-producing vaccines and medicines in existing production facilities

10-Jun-2020 - Siemens and Exyte join forces to offer end-to-end solutions for the biopharmaceutical industry by combining the digitalization expertise of Siemens with the innovation boost from Exyte. Against the background of the current challenges associated with the Covid-19 pandemic, pharmaceutical ...

OPTIMA pharma started a cooperation with Charité and the Berlin Institute of Health

The objective of this pilot project is to develop a production machine for cell and gene therapeutics

04-Apr-2019 - Optima Pharma and Charité – Universitätsmedizin Berlin are developing a concept for the automated production and filling of cell and gene therapeutics. These new types of medications are considered a promising new therapy opportunity for incurable cancer and metabolic diseases. They also pave the ...

Global trial shows CAR T therapy can lead to durable remissions in non-Hodgkin's lymphoma

04-Dec-2018 - In an update to a global clinical trial stretching from Philadelphia to four continents, the chimeric antigen receptor (CAR) T cell therapy Kymriah® (tisagenlecleucel, formerly CTL019) led to long-lasting remissions in patients with relapsed/refractory (r/r) diffuse large B-cell lymphoma (DLBCL). ...